Veracyte (VCYT) Stock Forecast, Price Target & Predictions


VCYT Stock Forecast


Veracyte stock forecast is as follows: an average price target of $35.00 (represents a -16.49% downside from VCYT’s last price of $41.91) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

VCYT Price Target


The average price target for Veracyte (VCYT) is $35.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $44.00 to $26.00. This represents a potential -16.49% downside from VCYT's last price of $41.91.

VCYT Analyst Ratings


Buy

According to 5 Wall Street analysts, Veracyte's rating consensus is 'Buy'. The analyst rating breakdown for VCYT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 0 'Hold' (0.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

Veracyte Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 07, 2024Mike MatsonNeedham$44.00$35.8522.74%4.99%
Aug 12, 2024Tejas SavantMorgan Stanley$26.00$29.41-11.58%-37.96%
May 04, 2022Morgan Stanley$23.00$21.009.55%-45.12%
May 04, 2022Needham$26.00$21.4621.16%-37.96%

The latest Veracyte stock forecast, released on Nov 07, 2024 by Mike Matson from Needham, set a price target of $44.00, which represents a 22.74% increase from the stock price at the time of the forecast ($35.85), and a 4.99% increase from VCYT last price ($41.91).

Veracyte Price Target by Period


1M3M12M
# Anlaysts-12
Avg Price Target-$44.00$35.00
Last Closing Price$41.91$41.91$41.91
Upside/Downside-100.00%4.99%-16.49%

In the current month, the average price target of Veracyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Veracyte's last price of $41.91. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2024UBSBuyInitialise
Oct 10, 2024GuggenheimBuyInitialise
Aug 12, 2024Morgan StanleyUnderweightUnderweightHold
Aug 07, 2024NeedhamBuyBuyHold
Aug 07, 2024William BlairOutperformOutperformHold
Jan 05, 2023ScotiabankSector OutperformInitialise

Veracyte's last stock rating was published by UBS on Oct 15, 2024. The company Initialise its VCYT rating from "null" to "Buy".

Veracyte Financial Forecast


Veracyte Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$98.20M$90.11M$90.32M$82.42M$80.30M$75.59M$72.86M$67.78M$67.34M$60.37M$55.10M$36.70M$34.54M$31.12M$20.70M$31.12M$29.73M$30.97M
Avg Forecast$142.14M$137.32M$133.50M$121.98M$129.58M$125.24M$122.62M$111.68M$116.64M$109.82M$100.27M$93.35M$91.97M$84.36M$83.05M$75.80M$73.94M$66.41M$68.08M$61.92M$62.52M$54.00M$48.07M$32.67M$32.20M$23.88M$17.08M$30.61M$29.57M$30.06M
High Forecast$148.27M$143.24M$139.25M$127.23M$135.16M$130.64M$127.90M$117.00M$117.72M$110.27M$100.27M$93.35M$95.93M$85.67M$86.63M$79.07M$76.76M$66.41M$68.08M$61.92M$62.52M$54.00M$48.07M$32.67M$32.20M$23.88M$17.08M$30.61M$29.57M$30.06M
Low Forecast$134.90M$130.32M$126.69M$115.76M$122.97M$118.86M$116.37M$106.48M$115.38M$109.36M$100.27M$93.35M$87.28M$83.08M$78.82M$71.94M$71.17M$66.41M$68.08M$61.92M$62.52M$54.00M$48.07M$32.67M$32.20M$23.88M$17.08M$30.61M$29.57M$30.06M
# Analysts444433357311185443435454587655
Surprise %------------1.07%1.07%1.09%1.09%1.09%1.14%1.07%1.09%1.08%1.12%1.15%1.12%1.07%1.30%1.21%1.02%1.01%1.03%

Veracyte's average Quarter revenue forecast for Mar 24 based on 1 analysts is $93.35M, with a low forecast of $93.35M, and a high forecast of $93.35M. VCYT's average Quarter revenue forecast represents a -4.93% decrease compared to the company's last Quarter revenue of $98.20M (Dec 23).

Veracyte EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433357311185443435454587655
EBITDA------------$5.03M-$-1.19M$-3.83M$1.14M$-3.36M$-5.34M$-7.75M$-4.91M$-9.28M$-4.63M$-43.06M$2.11M$-2.08M$-9.00M$-9.69M$-6.10M$295.00K
Avg Forecast$-20.43M$-19.74M$-19.19M$-17.53M$-18.63M$-18.00M$-17.63M$-16.06M$-16.77M$-15.79M$-14.41M$-20.42M$-13.22M$-12.13M$-11.94M$-18.56M$-5.74M$-7.78M$-7.97M$-16.87M$-7.32M$-6.32M$-5.63M$-135.64M$-3.77M$-2.80M$-2.00M$-7.75M$-3.46M$-3.52M
High Forecast$-19.39M$-18.73M$-18.21M$-16.64M$-17.68M$-17.09M$-16.73M$-15.31M$-16.59M$-15.72M$-14.41M$-16.33M$-12.55M$-11.94M$-11.33M$-14.85M$-4.59M$-7.78M$-7.97M$-13.50M$-7.32M$-6.32M$-5.63M$-108.51M$-3.77M$-2.80M$-2.00M$-6.20M$-3.46M$-3.52M
Low Forecast$-21.31M$-20.59M$-20.02M$-18.29M$-19.43M$-18.78M$-18.39M$-16.82M$-16.92M$-15.85M$-14.41M$-24.50M$-13.79M$-12.32M$-12.45M$-22.27M$-6.89M$-7.78M$-7.97M$-20.25M$-7.32M$-6.32M$-5.63M$-162.77M$-3.77M$-2.80M$-2.00M$-9.30M$-3.46M$-3.52M
Surprise %-------------0.38%-0.10%0.21%-0.20%0.43%0.67%0.46%0.67%1.47%0.82%0.32%-0.56%0.74%4.50%1.25%1.76%-0.08%

1 analysts predict VCYT's average Quarter EBITDA for Mar 24 to be $-20.42M, with a high of $-16.33M and a low of $-24.50M. This is -506.01% lower than Veracyte's previous annual EBITDA (Dec 23) of $5.03M.

Veracyte Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433357311185443435454587655
Net Income------------$-28.29M$-29.62M$-8.40M$-5.68M$-3.84M$-8.72M$-9.53M$-14.46M$-10.53M$-14.13M$-9.04M$-41.87M$26.86K$-4.12M$-11.03M$-11.72M$-7.46M$-730.00K
Avg Forecast$22.64M$20.10M$19.04M$15.36M$17.52M$15.18M$14.34M$9.82M$8.89M$2.55M$-1.29M$-20.41M$-7.87M$-11.49M$-11.95M$-18.56M$-12.30M$-19.93M$-17.20M$-16.87M$-12.39M$-13.12M$-19.41M$-131.88M$-7.46M$-16.20M$-20.53M$-9.37M$-6.30M$-5.66M
High Forecast$23.91M$21.23M$20.10M$16.22M$18.51M$16.03M$15.14M$11.45M$9.53M$2.69M$-1.20M$-16.33M$2.25M$-9.20M$-11.16M$-14.85M$-9.84M$-19.93M$-17.20M$-13.50M$-12.39M$-13.12M$-19.41M$-105.51M$-7.46M$-16.20M$-20.53M$-7.50M$-6.30M$-5.66M
Low Forecast$21.14M$18.77M$17.77M$14.34M$16.36M$14.18M$13.39M$8.18M$8.26M$2.38M$-1.36M$-24.50M$-14.62M$-13.03M$-12.62M$-22.27M$-14.77M$-19.93M$-17.20M$-20.25M$-12.39M$-13.12M$-19.41M$-158.26M$-7.46M$-16.20M$-20.53M$-11.25M$-6.30M$-5.66M
Surprise %------------3.59%2.58%0.70%0.31%0.31%0.44%0.55%0.86%0.85%1.08%0.47%0.32%-0.00%0.25%0.54%1.25%1.18%0.13%

Veracyte's average Quarter net income forecast for Mar 21 is $-131.88M, with a range of $-158.26M to $-105.51M. VCYT's average Quarter net income forecast represents a -491014.57% decrease compared to the company's last Quarter net income of $26.86K (Dec 20).

Veracyte SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433357311185443435454587655
SG&A------------$46.89M$40.68M$50.80M$48.59M$42.34M$43.28M$43.80M$44.15M$41.06M$47.46M$34.71M$62.17M$33.84M$19.11M$21.14M$25.03M$22.40M$19.35M
Avg Forecast$95.76M$92.51M$89.94M$82.18M$87.30M$84.38M$82.61M$75.24M$78.58M$73.98M$67.55M$63.05M$61.96M$56.83M$55.95M$57.32M$47.99M$44.54M$45.66M$52.11M$41.93M$36.22M$32.24M$21.91M$21.60M$16.02M$11.45M$20.02M$19.83M$20.16M
High Forecast$99.89M$96.50M$93.81M$85.72M$91.06M$88.01M$86.17M$78.82M$79.31M$74.29M$67.55M$75.66M$64.63M$57.72M$58.36M$68.79M$57.59M$44.54M$45.66M$62.53M$41.93M$36.22M$32.24M$21.91M$21.60M$16.02M$11.45M$24.03M$19.83M$20.16M
Low Forecast$90.88M$87.80M$85.35M$77.99M$82.85M$80.07M$78.40M$71.73M$77.73M$73.68M$67.55M$50.44M$58.80M$55.97M$53.10M$45.86M$38.39M$44.54M$45.66M$41.69M$41.93M$36.22M$32.24M$21.91M$21.60M$16.02M$11.45M$16.02M$19.83M$20.16M
Surprise %------------0.76%0.72%0.91%0.85%0.88%0.97%0.96%0.85%0.98%1.31%1.08%2.84%1.57%1.19%1.85%1.25%1.13%0.96%

Veracyte's average Quarter SG&A projection for Mar 24 is $63.05M, based on 1 Wall Street analysts, with a range of $50.44M to $75.66M. The forecast indicates a 34.46% rise compared to VCYT last annual SG&A of $46.89M (Dec 23).

Veracyte EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433357311185443435454587655
EPS------------$-0.39$-0.41$-0.12$-0.08$-0.05$-0.12$-0.13$-0.20$-0.15$-0.20$-0.13$-0.66-$-0.08$-0.22$-0.24$-0.15$-0.02
Avg Forecast$0.29$0.26$0.24$0.20$0.22$0.19$0.18$0.13$0.11$0.03$-0.02$-0.16$-0.10$-0.15$-0.15$-0.13$-0.15$-0.26$-0.22$-0.23$-0.16$-0.17$-0.25$-0.12$-0.10$-0.21$-0.27$-0.20$-0.08$-0.07
High Forecast$0.30$0.27$0.26$0.21$0.24$0.20$0.19$0.15$0.12$0.03$-0.02$-0.15$0.03$-0.12$-0.14$-0.13$-0.14$-0.26$-0.22$-0.23$-0.16$-0.17$-0.25$-0.12$-0.10$-0.21$-0.27$-0.20$-0.08$-0.07
Low Forecast$0.27$0.24$0.23$0.18$0.21$0.18$0.17$0.10$0.11$0.03$-0.02$-0.17$-0.19$-0.17$-0.16$-0.14$-0.16$-0.26$-0.22$-0.23$-0.16$-0.17$-0.25$-0.12$-0.10$-0.21$-0.27$-0.20$-0.08$-0.07
Surprise %------------3.89%2.80%0.79%0.59%0.35%0.46%0.58%0.86%0.93%1.18%0.52%5.50%-0.00%0.38%0.83%1.22%1.84%0.20%

According to 4 Wall Street analysts, Veracyte's projected average Quarter EPS for Mar 21 is $-0.12, with a low estimate of $-0.12 and a high estimate of $-0.12. This represents a -26017.92% decrease compared to VCYT previous annual EPS of - (Dec 20).

Veracyte Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$2.49$33.861259.84%Buy
ENTAEnanta Pharmaceuticals$5.58$65.671076.88%Buy
KROSKeros Therapeutics$16.10$101.00527.33%Buy
SLDBSolid Biosciences$4.14$17.50322.71%Buy
GPCRStructure Therapeutics$27.76$99.00256.63%Buy
ANABAnaptysBio$14.60$49.83241.30%Buy
RCKTRocket Pharmaceuticals$12.56$38.67207.88%Buy
QUREuniQure$17.94$53.67199.16%Buy
KURAKura Oncology$8.73$19.00117.64%Buy
SNDXSyndax Pharmaceuticals$14.37$30.60112.94%Buy
IDYAIDEAYA Biosciences$26.00$53.33105.12%Buy
MRUSMerus$43.16$81.2588.25%Buy
CYTKCytokinetics$49.36$90.0082.33%Buy
REPLReplimune Group$12.62$19.0050.55%Buy
PTGXProtagonist Therapeutics$39.57$57.3344.88%Buy
MGTXMeiraGTx$6.42$9.0040.19%Buy
CRNXCrinetics Pharmaceuticals$53.15$69.0029.82%Buy
RYTMRhythm Pharmaceuticals$59.62$67.6013.38%Buy
VRDNViridian Therapeutics$20.19$22.7512.68%Buy
VCYTVeracyte$41.91$35.00-16.49%Buy

VCYT Forecast FAQ


Is Veracyte a good buy?

Yes, according to 5 Wall Street analysts, Veracyte (VCYT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of VCYT's total ratings.

What is VCYT's price target?

Veracyte (VCYT) average price target is $35 with a range of $26 to $44, implying a -16.49% from its last price of $41.91. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Veracyte stock go up soon?

According to Wall Street analysts' prediction for VCYT stock, the company can go down by -16.49% (from the last price of $41.91 to the average price target of $35), up by 4.99% based on the highest stock price target, and down by -37.96% based on the lowest stock price target.

Can Veracyte stock reach $60?

VCYT's average twelve months analyst stock price target of $35 does not support the claim that Veracyte can reach $60 in the near future.

What are Veracyte's analysts' financial forecasts?

Veracyte's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $489.12M (high $510.7M, low $464.67M), average EBITDA is $-70.314M (high $-66.799M, low $-73.416M), average net income is $56.86M (high $61.13M, low $52.11M), average SG&A $329.52M (high $344.06M, low $313.05M), and average EPS is $0.725 (high $0.779, low $0.664). VCYT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $534.94M (high $557.99M, low $507.67M), average EBITDA is $-76.9M (high $-72.979M, low $-80.213M), average net income is $77.13M (high $81.45M, low $72.02M), average SG&A $360.39M (high $375.92M, low $342.02M), and average EPS is $0.983 (high $1.04, low $0.918).

Did the VCYT's actual financial results beat the analysts' financial forecasts?

Based on Veracyte's last annual report (Dec 2023), the company's revenue was $361.05M, beating the average analysts forecast of $335.18M by 7.72%. Apple's EBITDA was $12.92M, missing the average prediction of $-55.85M by -123.13%. The company's net income was $-74.404M, beating the average estimation of $-49.882M by 49.16%. Apple's SG&A was $184.78M, missing the average forecast of $232.07M by -20.38%. Lastly, the company's EPS was $-1.02, beating the average prediction of $-0.534 by 91.10%. In terms of the last quarterly report (Dec 2023), Veracyte's revenue was $98.2M, beating the average analysts' forecast of $91.97M by 6.77%. The company's EBITDA was $5.03M, missing the average prediction of $-13.221M by -138.04%. Veracyte's net income was $-28.293M, beating the average estimation of $-7.875M by 259.29%. The company's SG&A was $46.89M, missing the average forecast of $61.96M by -24.32%. Lastly, the company's EPS was $-0.39, beating the average prediction of $-0.1 by 288.60%